INVESTORS MEDIA HOME - Mesoblast The Investor Relations website contains information about Mesoblast's business for stockholders, potential investors, and financial analysts
Mesoblast Receives IND Clearance from FDA to Directly . . . - BioSpace Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms Ryoncil ® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease
Mesoblast - Wikipedia Mesoblast Limited is an Australian regenerative medicine company It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain
Inside Mesoblasts Playbook For Making Allogeneic Cell Therapy Real I sat down with Mesoblast’s CEO Silviu Itescu to learn how the company built its mesenchymal stromal cell (MSC) platform, secured the first and only FDA‑approved MSC product in the U S , and is now leveraging that foundation across a suite of high‑need inflammatory indications
Mesoblast: The Building Block of Muscle, Bone, and Blood A mesoblast is essentially a blank slate, a formative cell that holds the potential to become a significant portion of the organism Their appearance marks a fundamental step in the process of building a complex living being from a simple collection of cells
FDA clears Mesoblast for registrational trial in DMD Additionally, Mesoblast cited strong preclinical data demonstrating efficacy in DMD models and the existence of an FDA-approved manufacturing process already in place DMD is a genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys